Block Listing Application

RNS Number : 8564R

LungLife AI, INC

10 November 2021

 

LungLife AI, Inc.

("LungLife" or the "Company")

Block Listing Application

LungLife AI (AIM: LLAI), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that a block listing application (the "Block Admission") has been made to the London Stock Exchange for up to 1,356,139 common shares of US $0.0001 each (the "Block Listing Shares") to be admitted to trading on AIM ("Admission").

The common shares that are being reserved under this block listing application will be issued by the Company, as required, in order to satisfy the exercise of share options and vested awards pursuant to the terms of the following share plans (the "Schemes"):

Scheme	No. of common shares under block listing application
2010 Stock Incentive Plan	480,775
2020 Stock Incentive Plan	201,374
2021 Omnibus Long-Term Incentive Plan	673,990

The Block Listing Shares will, upon issue, rank equally with all other common shares of US $0.0001 each in the capital of the Company that are then in issue. The Block Listing Admission is expected to become effective on 15 November 2021.

For further information please contact:

LungLife AI, Inc.	www.lunglifeai.com
Paul Pagano, CEO	Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser & Broker)	Tel: [phone]
Daniel Adams / Virginia Bull / Cameron MacRitchie
Walbrook PR Limited	Tel: [phone] or  [e-mail]
Paul McManus / Alice Woodings	Mob: [phone]

 

END

 

 

ALSFSLFWUEFSEFF